{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:07Z","timestamp":1791873427309,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3M1721"],"award-info":[{"award-number":["CMRPG3M1721"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Council, Taiwan","award":["NMRPD1P1141"],"award-info":[{"award-number":["NMRPD1P1141"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04308-z","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:20:07Z","timestamp":1769491207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-6417","authenticated-orcid":false,"given":"I.-Wen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-7030","authenticated-orcid":false,"given":"Cheng-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chung","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4308_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4308_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Pinyol R, Kelley RK et al (2022) Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 3:386\u2013401","journal-title":"Nat Cancer"},{"key":"4308_CR3","doi-asserted-by":"crossref","unstructured":"Cappuyns S, Corbett V, Yarchoan M, et al. (2023) Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: A review. JAMA Oncol","DOI":"10.1001\/jamaoncol.2023.2677"},{"key":"4308_CR4","doi-asserted-by":"publisher","DOI":"10.1159\/000537686","author":"W Teng","year":"2024","unstructured":"Teng W, Wang H-W, Lin S-M (2024) Management consensus guidelines for hepatocellular carcinoma: 2023 update on surveillance, diagnosis, systemic treatment, and posttreatment monitoring by the taiwan liver cancer association and the gastroenterological society of taiwan. Liver Cancer. https:\/\/doi.org\/10.1159\/000537686","journal-title":"Liver Cancer"},{"key":"4308_CR5","doi-asserted-by":"crossref","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. (2023) Aasld practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology","DOI":"10.1097\/HEP.0000000000000466"},{"key":"4308_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) Bclc strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76:681\u2013693","journal-title":"J Hepatol"},{"key":"4308_CR7","unstructured":"National comprehensive cancer network. Hepatobiliary cancer (version 5.2022). https:\/\/www.Nccn.Org\/professionals\/physician_gls\/pdf\/hepatobiliary.Pdf. Accessed january 13, 2023. 2022"},{"key":"4308_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su GL, Altayar O, O\u2019Shea R et al (2022) Aga clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology 162:920\u2013934","journal-title":"Gastroenterology"},{"key":"4308_CR9","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK et al (2024) Systemic therapy for advanced hepatocellular carcinoma: Asco guideline update. J Clin Oncol 42:1830\u20131850","journal-title":"J Clin Oncol"},{"key":"4308_CR10","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","volume":"18","author":"G Lau","year":"2024","unstructured":"Lau G, Obi S, Zhou J et al (2024) Apasl clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatol Int 18:1661\u20131683","journal-title":"Hepatol Int"},{"issue":"2","key":"4308_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, Mazzaferro V, Jepsen P, Golfieri R, Galle P, Dawson L, Reig M (2025) Easl clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol 82(2):315\u201374","journal-title":"J Hepatol"},{"key":"4308_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"4308_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG et al (2018) Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28:1243\u20131251","journal-title":"Thyroid"},{"key":"4308_CR14","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"4308_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from imbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862\u2013873","journal-title":"J Hepatol"},{"key":"4308_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1010279","volume":"13","author":"A Chera","year":"2022","unstructured":"Chera A, Stancu AL, Bucur O (2022) Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol (Lausanne) 13:1010279","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4308_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1210\/edrv-3-2-164","volume":"3","author":"L Wartofsky","year":"1982","unstructured":"Wartofsky L, Burman KD (1982) Alterations in thyroid function in patients with systemic illness: the \u201ceuthyroid sick syndrome.\u201d Endocr Rev 3:164\u2013217","journal-title":"Endocr Rev"},{"key":"4308_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2021.08.009","volume":"161","author":"N Zhou","year":"2021","unstructured":"Zhou N, Velez MA, Bachrach B et al (2021) Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in nsclc. Lung Cancer 161:34\u201341","journal-title":"Lung Cancer"},{"key":"4308_CR19","first-page":"27","volume":"52","author":"AH Zargar","year":"2004","unstructured":"Zargar AH, Ganie MA, Masoodi SR et al (2004) Prevalence and pattern of sick euthyroid syndrome in acute and chronic non-thyroidal illness\u2013its relationship with severity and outcome of the disorder. J Assoc Physicians India 52:27\u201331","journal-title":"J Assoc Physicians India"},{"key":"4308_CR20","doi-asserted-by":"crossref","unstructured":"Bruinstroop E, van der Spek AH, Boelen A (2023) Role of hepatic deiodinases in thyroid hormone homeostasis and liver metabolism, inflammation, and fibrosis. Eur Thyroid J. 12","DOI":"10.1530\/ETJ-22-0211"},{"key":"4308_CR21","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s40618-020-01482-4","volume":"44","author":"E Fliers","year":"2021","unstructured":"Fliers E, Boelen A (2021) An update on non-thyroidal illness syndrome. J Endocrinol Invest 44:1597\u20131607","journal-title":"J Endocrinol Invest"},{"issue":"14","key":"4308_CR22","doi-asserted-by":"publisher","first-page":"11546","DOI":"10.3390\/ijms241411546","volume":"24","author":"K Yamada","year":"2023","unstructured":"Yamada K, Tanaka T, Kai K et al (2023) Suppression of nash-related hcc by farnesyltransferase inhibitor through inhibition of inflammation and hypoxia-inducible factor-1alpha expression. Int J Mol Sci. 24(14):11546","journal-title":"Int J Mol Sci."},{"issue":"1","key":"4308_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V (2018) Easl clinical practice guidelines: Management of hepatocellular carcinoma. J hepatol 69(1):182\u2013236","journal-title":"J hepatol"},{"key":"4308_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified recist (mrecist) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360","journal-title":"Semin Liver Dis"},{"key":"4308_CR25","doi-asserted-by":"publisher","first-page":"S1304","DOI":"10.1016\/j.annonc.2020.10.190","volume":"31","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ikeda M, Zhu AX et al (2020) 169p imbrave150: management of adverse events of special interest (aesis) for atezolizumab (atezo) and bevacizumab (bev) in unresectable hcc. Ann Oncol 31:S1304\u2013S1305","journal-title":"Ann Oncol"},{"key":"4308_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000531182","volume":"13","author":"YS Song","year":"2024","unstructured":"Song YS, Yang H, Kang B et al (2024) Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma. Liver Cancer 13:89\u201398","journal-title":"Liver Cancer"},{"key":"4308_CR27","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M et al (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101:4431\u20134439","journal-title":"J Clin Endocrinol Metab"},{"key":"4308_CR28","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1186\/s12885-020-07508-7","volume":"20","author":"CE Wu","year":"2020","unstructured":"Wu CE, Yang CK, Peng MT et al (2020) The association between immune-related adverse events and survival outcomes in asian patients with advanced melanoma receiving anti-pd-1 antibodies. BMC Cancer 20:1018","journal-title":"BMC Cancer"},{"key":"4308_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"Lima Ferreira J, Costa C, Marques B et al (2021) Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 70:299\u2013309","journal-title":"Cancer Immunol Immunother"},{"key":"4308_CR30","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","volume":"71","author":"YM Cheung","year":"2022","unstructured":"Cheung YM, Wang W, McGregor B, Hamnvik OR (2022) Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 71:1795\u20131812","journal-title":"Cancer Immunol Immunother"},{"key":"4308_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M (2020) Pd-l1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30:177\u2013184","journal-title":"Thyroid"},{"key":"4308_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1673635","volume":"9","author":"Y Ma","year":"2020","unstructured":"Ma Y, Yang H, Kroemer G (2020) Endogenous and exogenous glucocorticoids abolish the efficacy of immune-dependent cancer therapies. Oncoimmunology 9:1673635","journal-title":"Oncoimmunology"},{"key":"4308_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_430028","volume":"44","author":"P Ntellas","year":"2024","unstructured":"Ntellas P, Chau I (2024) Updates on systemic therapy for hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 44:e430028","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4308_CR34","first-page":"63","volume":"14","author":"A Sara","year":"2023","unstructured":"Sara A, Ruff SM, Noonan AM, Pawlik TM (2023) Real-world use of immunotherapy for hepatocellular carcinoma. Pragmat Obs Res 14:63\u201374","journal-title":"Pragmat Obs Res"},{"key":"4308_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12672-014-0183-0","volume":"5","author":"ZA Yasar","year":"2014","unstructured":"Yasar ZA, Kirakli C, Yilmaz U et al (2014) Can non-thyroid illness syndrome predict mortality in lung cancer patients? A prospective cohort study. Horm Cancer 5:240\u2013246","journal-title":"Horm Cancer"},{"key":"4308_CR36","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.18632\/oncotarget.14376","volume":"8","author":"A Bunevicius","year":"2017","unstructured":"Bunevicius A, Deltuva VP, Tamasauskas S et al (2017) Preoperative low tri-iodothyronine concentration is associated with worse health status and shorter five year survival of primary brain tumor patients. Oncotarget 8:8648\u20138656","journal-title":"Oncotarget"},{"key":"4308_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bjh.14528","volume":"177","author":"R Gao","year":"2017","unstructured":"Gao R, Liang JH, Wang L et al (2017) Low t3 syndrome is a strong prognostic predictor in diffuse large b cell lymphoma. Br J Haematol 177:95\u2013105","journal-title":"Br J Haematol"},{"key":"4308_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/ijc.31327","volume":"143","author":"R Gao","year":"2018","unstructured":"Gao R, Chen RZ, Xia Y et al (2018) Low t3 syndrome as a predictor of poor prognosis in chronic lymphocytic leukemia. Int J Cancer 143:466\u2013477","journal-title":"Int J Cancer"},{"key":"4308_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221094422","volume":"21","author":"Q Pan","year":"2022","unstructured":"Pan Q, Jian Y, Zhang Y et al (2022) The association between low t3 syndrome and survival in patients with newly diagnosed multiple myeloma: a retrospective study. Technol Cancer Res Treat 21:15330338221094422","journal-title":"Technol Cancer Res Treat"},{"key":"4308_CR40","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3803\/EnM.2021.1198","volume":"36","author":"L Sabatino","year":"2021","unstructured":"Sabatino L, Vassalle C, Del Seppia C, Iervasi G (2021) Deiodinases and the three types of thyroid hormone deiodination reactions. Endocrinol Metab 36:952\u2013964","journal-title":"Endocrinol Metab"},{"key":"4308_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052238","author":"N Nagai","year":"2021","unstructured":"Nagai N, Kudo Y, Aki D et al (2021) Immunomodulation by inflammation during liver and gastrointestinal tumorigenesis and aging. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22052238","journal-title":"Int J Mol Sci"},{"key":"4308_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.850328","volume":"13","author":"S Sciacchitano","year":"2022","unstructured":"Sciacchitano S, Capalbo C, Napoli C et al (2022) Nonthyroidal illness syndrome: to treat or not to treat? Have we answered the question? A review of metanalyses. Front Endocrinol (Lausanne) 13:850328","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4308_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2019.00059","volume":"10","author":"E Krashin","year":"2019","unstructured":"Krashin E, Piekielko-Witkowska A, Ellis M, Ashur-Fabian O (2019) Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne) 10:59","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04308-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:20:09Z","timestamp":1769491209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04308-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4308"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04308-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted following the Declaration of Helsinki and approved by Institutional Review Board (IRB No. 202200991B0C501). Due to the retrospective nature of this study, informed consent was waived by the Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"59"}}